Your browser doesn't support javascript.
loading
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy, Pablo; Fernández-Ramos, David; Lopitz-Otsoa, Fernando; Simón, Jorge; Barbier-Torres, Lucía; Gomez-Santos, Beatriz; Nuñez-Garcia, Maitane; Azkargorta, Mikel; Gutiérrez-de Juan, Virginia; Serrano-Macia, Marina; Rodríguez-Agudo, Rubén; Iruzubieta, Paula; Anguita, Juan; Castro, Rui E; Champagne, Devin; Rincón, Mercedes; Elortza, Felix; Arslanow, Anita; Krawczyk, Marcin; Lammert, Frank; Kirchmeyer, Mélanie; Behrmann, Iris; Crespo, Javier; Lu, Shelly C; Mato, José M; Varela-Rey, Marta; Aspichueta, Patricia; Delgado, Teresa C; Martínez-Chantar, María L.
Afiliação
  • Fernández-Tussy P; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: pablo.fernandeztussy@yale.edu.
  • Fernández-Ramos D; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: dfernandez@cicbiogune.es.
  • Lopitz-Otsoa F; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: flopitz@cicbiogune.es.
  • Simón J; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: jsimon@cicbiogune.es.
  • Barbier-Torres L; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: Lucia.BarbierTorres@cshs.org.
  • Gomez-Santos B; Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, 48940, Leioa, Bizkaia, Spain; Biocruces Health Research Institute, Barakaldo, Spain. Electronic address: bgomezsantos@gmail.com.
  • Nuñez-Garcia M; Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, 48940, Leioa, Bizkaia, Spain; Biocruces Health Research Institute, Barakaldo, Spain. Electronic address: maitane.nunez@gmail.com.
  • Azkargorta M; Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio, 48160, Spain. Electronic address: mazkargorta@cicbiogune.es.
  • Gutiérrez-de Juan V; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: vgutierrez@cicbiogune.es.
  • Serrano-Macia M; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: mserrano@cicbiogune.es.
  • Rodríguez-Agudo R; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: rrodriguez@cicbiogune.es.
  • Iruzubieta P; Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, 39008
  • Anguita J; Macrophage and Tick Vaccine Laboratory, CIC bioGUNE, Bizkaia Science and Technology Park, Derio 48160 Bizkaia, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, 48013, Spain. Electronic address: janguita@cicbiogune.es.
  • Castro RE; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. Electronic address: ruieduardocastro@ff.ulisboa.pt.
  • Champagne D; Department of Medicine, University of Vermont College of Medicine, Burlington, 05405, VT, USA. Electronic address: Devin.Champagne@uvm.edu.
  • Rincón M; Department of Medicine, University of Vermont College of Medicine, Burlington, 05405, VT, USA. Electronic address: Mercedes.Rincon@med.uvm.edu.
  • Elortza F; Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio, 48160, Spain. Electronic address: felortza@cicbiogune.es.
  • Arslanow A; Department of Medicine II, Saarland University Medical Center, 66421, Homburg, Germany. Electronic address: anita.arslanow@uks.eu.
  • Krawczyk M; Department of Medicine II, Saarland University Medical Center, 66421, Homburg, Germany. Electronic address: marcin.krawczyk@uks.eu.
  • Lammert F; Department of Medicine II, Saarland University Medical Center, 66421, Homburg, Germany. Electronic address: frank.lammert@uks.eu.
  • Kirchmeyer M; Signal Transduction Laboratory, Life Sciences Research Unit, University of Luxembourg, House of Biomedicine II, 4367, Belvaux, Luxembourg. Electronic address: kirchmeyer.melanie@gmail.com.
  • Behrmann I; Signal Transduction Laboratory, Life Sciences Research Unit, University of Luxembourg, House of Biomedicine II, 4367, Belvaux, Luxembourg. Electronic address: iris.behrmann@uni.lu.
  • Crespo J; Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, 39008
  • Lu SC; Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Shelly.Lu@cshs.org.
  • Mato JM; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: director@cicbiogune.es.
  • Varela-Rey M; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: mvarela@cicbiogune.es.
  • Aspichueta P; Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, 48940, Leioa, Bizkaia, Spain; Biocruces Health Research Institute, Barakaldo, Spain. Electronic address: patricia.aspichueta@ehu.es.
  • Delgado TC; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: tcardoso@cicbiogune.es.
  • Martínez-Chantar ML; Liver disease Laboratory, Liver metabolism Laboratory, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 48160, Derio, Bizkaia, Spain. Electronic address: mlmartinez@cicbiogune.es.
Mol Metab ; 29: 40-54, 2019 11.
Article em En | MEDLINE | ID: mdl-31668391
ABSTRACT

OBJECTIVE:

Non-alcoholic fatty liver disease (NAFLD) is a complex pathology in which several dysfunctions, including alterations in metabolic pathways, mitochondrial functionality and unbalanced lipid import/export, lead to lipid accumulation and progression to inflammation and fibrosis. The enzyme glycine N-methyltransferase (GNMT), the most important enzyme implicated in S-adenosylmethionine catabolism in the liver, is downregulated during NAFLD progression. We have studied the mechanism involved in GNMT downregulation by its repressor microRNA miR-873-5p and the metabolic pathways affected in NAFLD as well as the benefit of recovery GNMT expression.

METHODS:

miR-873-5p and GNMT expression were evaluated in liver biopsies of NAFLD/NASH patients. Different in vitro and in vivo NAFLD murine models were used to assess miR-873-5p/GNMT involvement in fatty liver progression through targeting of the miR-873-5p as NAFLD therapy.

RESULTS:

We describe a new function of GNMT as an essential regulator of Complex II activity in the electron transport chain in the mitochondria. In NAFLD, GNMT expression is controlled by miR-873-5p in the hepatocytes, leading to disruptions in mitochondrial functionality in a preclinical murine non-alcoholic steatohepatitis (NASH) model. Upregulation of miR-873-5p is shown in the liver of NAFLD/NASH patients, correlating with hepatic GNMT depletion. Importantly, NASH therapies based on anti-miR-873-5p resolve lipid accumulation, inflammation and fibrosis by enhancing fatty acid ß-oxidation in the mitochondria. Therefore, miR-873-5p inhibitor emerges as a potential tool for NASH treatment.

CONCLUSION:

GNMT participates in the regulation of metabolic pathways and mitochondrial functionality through the regulation of Complex II activity in the electron transport chain. In NAFLD, GNMT is repressed by miR-873-5p and its targeting arises as a valuable therapeutic option for treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Complexo II de Transporte de Elétrons / Glicina N-Metiltransferase / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Complexo II de Transporte de Elétrons / Glicina N-Metiltransferase / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2019 Tipo de documento: Article